ClinicalTrials.gg
CompletedNCT05322707Updated Aug 30, 2023

BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient

A Phase 3 interventional study of Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg and Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol in Asthma, sponsored by Cipla Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by Cipla Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,485
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
10th of 108
1,485 · median 124
Started
2022
with 2 others
Phase 3
51 of 110
3 open now
Registered
103rd of 110
by date

Among the 110 studies testing budesonide in Asthma, this one is the 10th largest by enrollment of the 108 interventional ones that give a count, is one of 3 that started in 2022, is one of 51 in phase 3, and was the 103rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate the Pharmacodynamic bioequivalence of the test product to the reference product in adult patient with Asthma

Read the detailed description

This study is to demonstrate the Pharmacodynamic bioequivalence of the test product to the reference product in terms of FEV1 measures at different timepoints in adult patient with Asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients who are 18-70 years of age
  • Has moderate-to-severe asthma with a pre-bronchodilator of ≥45% and \<80% of the predicted normal value for the patient after withholding bronchodilators
  • Has ≥15% and ≥0.20 L reversibility of FEV1 within 30 minutes following administration of 360 μg of albuterol (pMDI)
  • Is stable on current chronic asthma treatment (documented asthma diagnosis and/or prescription for asthma medications) for at least 4 weeks prior to screening visit (Visit 1).
  • Has been diagnosed with asthma as defined by the National Asthma Education and Prevention Program (NAEPP 2007) at least 6 months prior to screening
  • Adult male or female patients of non-childbearing or of committed to consistent and correct use of an acceptable method of

Exclusion criteria

Exclusion Criteria:

  • Has history of life-threatening asthma defined as an asthma episode(s) that required intubation and/or was associated with hypercapnia, respiratory arrest, or hypoxic seizures, asthma related syncopal episode(s), within past 1 year or during run-in period
  • Has history of any asthma-related hospitalizations within the past one year prior to screening visit (Visit 1) or during the run-in period
  • Has history of any pulmonary disorder other than asthma, including but not limited to: diagnosis of (COPD), interstitial lung disease, cystic fibrosis, bronchiectasis, chronic bronchitis, pulmonary hypertension, active pulmonary tuberculosis, or pulmonary carcinoma.
  • Has current evidence of bronchopulmonary dysplasia or pulmonary fibrosis
  • Has recent respiratory tract infection that is not resolved within 4 weeks of screening and is considered significant in the opinion of the investigator
  • Patients who, in the opinion of the investigator, significantly abuse alcohol or drugs, will be excluded.
  • Is taking any medications within 4 weeks prior to the screening and during the study
  • Use of systemic or oral within 2 months or intramuscular depot corticosteroid treatment 90 days prior to the screening or during the run-in period for any reason other than asthma.
  • Women of who are lactating or pregnant at screening visit, as documented by a positive screening pregnancy test.
  • Has previously been randomized in this study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,485 participants (actual)

Study arms

  • Experimental
    Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg

    Inhalation Aerosol, 2 actuations orally inhaled twice daily

    Drug: Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg

  • Active comparator
    Symbicort®

    Inhalation Aerosol, 2 actuations orally inhaled twice daily

    Drug: Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol

  • Placebo comparator
    Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg

    Inhalation Aerosol, 2 actuations orally inhaled twice daily

    Drug: Placebo

Interventions

  • DrugBudesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg

    Drug page: Budesonide

    Inhalation aerosol, 2 actuations orally inhaled twice daily

    Also known as: Test product

  • DrugSymbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol

    Inhalation aerosol, 2 actuations orally inhaled twice daily

    Also known as: RLD

  • DrugPlacebo

    Inhalation aerosol, 2 actuations orally inhaled twice daily

    Also known as: Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg

06

What researchers measure

Primary outcomes

  1. Area under the serial Force Expiration volume1

    Area under the serial Force Expiration volume1 from time 0 to 12 hours (AUC0-12 hours) on the first day of the treatment

    Time frame: From time 0 to 12 hours

  2. Change in FEV1 from baseline

    FEV1 measured in the morning prior to the dosing of inhaled medication on the last day of the 6 weeks treatment

    Time frame: 6 weeks treatment

Secondary outcomes

  1. Number and Severity of Adverse Events and Serious Adverse Events

    Assessment of No. of AEs, its severity, and relatedness and SAE.,

    Time frame: 6 weeks treatment

  2. Assessment of vital signs: Pulse rate

    Assessment of vital signs

    Time frame: 6 weeks treatment

  3. Number of participants with suspected oral infection performed with an oropharyngeal examination

    Assessment of physical examination including oropharyngeal examination

    Time frame: 6 weeks treatment

  4. Assessment of vital signs: Systolic and diastolic Blood Pressures

    Assessment of vital signs: Systolic and diastolic Blood Pressures

    Time frame: 6 weeks treatment

07

Study locations

1 site
  • Velocity Clinical Research
    Medford, Oregon 97504, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Aug 2023, 16 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 16 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2022
First posted
Apr 12, 2022
StartActual
Apr 15, 2022
Primary completionActual
Aug 15, 2023
CompletionActual
Aug 29, 2023
Last update
Aug 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05322707
Lead sponsor
Cipla Ltd.
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
Apr 15, 2022
Primary completion
Aug 15, 2023
Completion
Aug 29, 2023
Last update
Aug 30, 2023

Study contacts

Orlando Rivero, MD
principal investigator · Global Research Solution

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion